Targeting chemokine receptor CXCR7 inhibits glioma cell proliferation and mobility

Anticancer Research

Volumn 35, Issue 1, 2015, Pages 53-64

  Liu, Yang ^a   Carson Walter, Eleanor ^a   Walter, Kevin A ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

CXCL12; CXCR7; Glioma; Mobility; Proliferation

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; CHEMOKINE RECEPTOR CXCR7 ANTAGONIST; CHEMOKINE RECEPTORCCX771 ANTAGONIST; MITOGEN ACTIVATED PROTEIN KINASE 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR; CXCL12 PROTEIN, HUMAN; CXCR7 PROTEIN, HUMAN; STROMAL CELL DERIVED FACTOR 1;

ARTICLE; CANCER CELL LINE; CANCER PATIENT; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; STEM CELL; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; GENE SILENCING; GENETICS; GLIOMA; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CXCL12; DRUG SCREENING ASSAYS, ANTITUMOR; GENE KNOCKDOWN TECHNIQUES; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASTIC STEM CELLS; RECEPTORS, CXCR;

EID: 84920421505     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, Arenzana-Seisdedos F, Thelen M and Bachelerie F: The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 280: 35760-35766, 2005.
2. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MC and Schall TJ: A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 203: 2201-2213, 2006.
3. Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, Mehra R, Loberg R and Taichman RS: The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 283: 4283-4294, 2008.
4. Iwakiri S, Mino N, Takahashi T, Sonobe M, Nagai S, Okubo K, Wada H, Date H and Miyahara R: Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. Cancer 115: 2580-2593, 2009.
5. Yates TJ, Knapp J, Gosalbez M, Lokeshwar SD, Gomez CS, Benitez A, Ekwenna OO, Young EE, Manoharan M and Lokeshwar VB: C-X-C chemokine receptor 7: a functionally associated molecular marker for bladder cancer. Cancer 119: 61-71, 2013.
6. Wani N, Nasser MW, Ahirwar DK, Zhao H, Miao Z, Shilo K and Ganju RK: C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment. Breast Cancer Res 16: R54, 2014.
7. Gebauer F, Tachezy M, Effenberger K, von Loga K, Zander H, Marx A, Kaifi JT, Sauter G, Izbicki JR and Bockhorn M: Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. J Surg Oncol 104: 140-145, 2011.
8. Schrevel M, Karim R, ter Haar NT, van der Burg SH, Trimbos JB, Fleuren GJ, Gorter A and Jordanova ES: CXCR7 expression is associated with disease-free and disease-specific survival in cervical cancer patients. Br J Cancer 106: 1520-1525, 2012.
9. Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, Kleer CG, Essner JJ, Nasevicius A, Luker GD, Howard MC and Schall TJ: CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumorassociated vasculature. Proc Natl Acad Sci USA 104: 15735-15740, 2007.
10. Hernandez L, Magalhaes MA, Coniglio SJ, Condeelis JS and Segall JE: Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Res 13: R128, 2011.
11. Raggo C, Ruhl R, McAllister S, Koon H, Dezube BJ, Fruh K and Moses AV: Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus. Cancer Res 65: 5084-5095, 2005.
12. Maussang D, Mujic-Delic A, Descamps FJ, Stortelers C, Vanlandschoot P, Stigter-van Walsum M, Vischer HF, van Roy M, Vosjan M, Gonzalez-Pajuelo M, van Dongen GA, Merchiers P, van Rompaey P and Smit MJ: Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo. J Biol Chem 288: 29562-29572, 2013.
13. Hartmann TN, Grabovsky V, Pasvolsky R, Shulman Z, Buss EC, Spiegel A, Nagler A, Lapidot T, Thelen M and Alon R: A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells. J Leukoc Biol 84: 1130-1140, 2008.
14. Zabel BA, Wang Y, Lewen S, Berahovich RD, Penfold ME, Zhang P, Powers J, Summers BC, Miao Z, Zhao B, Jalili A, Janowska-Wieczorek A, Jaen JC and Schall TJ: Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol 183: 3204-3211, 2009.
15. Madden SL, Cook BP, Nacht M, Weber WD, Callahan MR, Jiang Y, Dufault MR, Zhang X, Zhang W, Walter-Yohrling J, Rouleau C, Akmaev VR, Wang CJ, Cao X, St Martin TB, Roberts BL, Teicher BA, Klinger KW, Stan RV, Lucey B, Carson-Walter EB, Laterra J and Walter KA: Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol 165: 601-608, 2004.
16. Liu Y, Carson-Walter EB, Cooper A, Winans BN, Johnson MD and Walter KA: Vascular gene expression patterns are conserved in primary and metastatic brain tumors. J Neurooncol 99: 13-24, 2010.
17. Hattermann K, Held-Feindt J, Lucius R, Muerkoster SS, Penfold ME, Schall TJ and Mentlein R: The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res 70: 3299-3308, 2010.
18. Calatozzolo C, Canazza A, Pollo B, Di Pierro E, Ciusani E, Maderna E, Salce E, Sponza V, Frigerio S, Di Meco F, Schinelli S and Salmaggi A: Expression of the new CXCL12 receptor, CXCR7, in gliomas. Cancer Biol Ther 11: 242-253, 2011.
19. Walters MJ, Ebsworth K, Berahovich RD, Penfold ME, Liu SC, Al Omran R, Kioi M, Chernikova SB, Tseng D, Mulkearns-Hubert EE, Sinyuk M, Ransohoff RM, Lathia JD, Karamchandani J, Kohrt HE, Zhang P, Powers JP, Jaen JC, Schall TJ, Merchant M, Recht L and Brown JM: Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats. Br J Cancer 110: 1179-1188, 2014.
20. Liu C, Pham K, Luo D, Reynolds BA, Hothi P, Foltz G and Harrison JK: Expression and functional heterogeneity of chemokine receptors CXCR4 and CXCR7 in primary patientderived glioblastoma cells. PLoS One 8: e59750, 2013.
21. Salmaggi A, Maderna E, Calatozzolo C, Gaviani P, Canazza A, Milanesi I, Silvani A, DiMeco F, Carbone A and Pollo B: CXCL12, CXCR4 and CXCR7 expression in brain metastases. Cancer Biol Ther 8: 1608-1614, 2009.
22. Wurth R, Barbieri F, Bajetto A, Pattarozzi A, Gatti M, Porcile C, Zona G, Ravetti JL, Spaziante R and Florio T: Expression of CXCR7 chemokine receptor in human meningioma cells and in intratumoral microvasculature. J Neuroimmunol 234: 115-123, 2011.
23. Hattermann K, Mentlein R and Held-Feindt J: CXCL12 mediates apoptosis resistance in rat C6 glioma cells. Oncol Rep 27: 1348-1352, 2012.
24. Carson-Walter EB, Hampton J, Shue E, Geynisman DM, Pillai PK, Sathanoori R, Madden SL, Hamilton RL and Walter KA: Plasmalemmal vesicle associated protein-1 is a novel marker implicated in brain tumor angiogenesis. Clin Cancer Res 11: 7643-7650, 2005.
25. Liu Y, Carson-Walter E and Walter KA: Chemokine Receptor CXCR7 Is a Functional Receptor for CXCL12 in Brain Endothelial Cells. PLoS One 9: e103938, 2014.
26. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F and Vescovi A: Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64: 7011-7021, 2004.
27. Auvergne RM, Sim FJ, Wang S, Chandler-Militello D, Burch J, Al Fanek Y, Davis D, Benraiss A, Walter K, Achanta P, Johnson M, Quinones-Hinojosa A, Natesan S, Ford HL and Goldman SA: Transcriptional differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes. Cell Rep 3: 2127-2141, 2013.
28. Shue EH, Carson-Walter EB, Liu Y, Winans BN, Ali ZS, Chen J and Walter KA: Plasmalemmal vesicle associated protein-1 (PV-1) is a marker of blood-brain barrier disruption in rodent models. BMC Neurosci 9: 29, 2008.
29. Berahovich RD, Penfold ME and Schall TJ: Nonspecific CXCR7 antibodies. Immunol Lett 133: 112-114, 2010.
30. Boldajipour B, Mahabaleshwar H, Kardash E, Reichman-Fried M, Blaser H, Minina S, Wilson D, Xu Q and Raz E: Control of chemokine-guided cell migration by ligand sequestration. Cell 132: 463-473, 2008.
31. Naumann U, Cameroni E, Pruenster M, Mahabaleshwar H, Raz E, Zerwes HG, Rot A and Thelen M: CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS One 5: e9175, 2010.
32. Luker KE, Steele JM, Mihalko LA, Ray P and Luker GD: Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Oncogene 29: 4599-4610, 2010.
33. Luker KE, Lewin SA, Mihalko LA, Schmidt BT, Winkler JS, Coggins NL, Thomas DG and Luker GD: Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene 31: 4750-4758, 2012.